Multiple sclerosis: time for early treatment with high-efficacy drugs

K Selmaj, BAC Cree, M Barnett, A Thompson… - Journal of …, 2024 - Springer
This review addresses current changes in the approach to treating patients with multiple
sclerosis (MS). The widely practiced approach of utilizing agents with lower treatment …

Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: methotrexate, alkylating agents, biologics, and small molecule inhibitors

MA Kreher, S Konda, MMB Noland, MI Longo… - Journal of the American …, 2023 - Elsevier
In solid organ transplant recipients, skin cancer risk associated with posttransplant
immunosuppression has been well-described, and screening practices generally reflect …

Novel potential pharmacological applications of dimethyl fumarate—an overview and update

G Bresciani, F Manai, S Davinelli, P Tucci… - Frontiers in …, 2023 - frontiersin.org
Dimethyl fumarate (DMF) is an FDA-approved drug for the treatment of psoriasis and
multiple sclerosis. DMF is known to stabilize the transcription factor Nrf2, which in turn …

Adverse drug reactions with drugs used in multiple sclerosis: an analysis from the Italian pharmacovigilance database

MA Barbieri, EE Sorbara, A Battaglia… - Frontiers in …, 2022 - frontiersin.org
Given the importance of inflammation at the onset of multiple sclerosis (MS), therapy is
mainly based on the use of anti-inflammatory drugs including disease modifying therapies …

Clinical use of dimethyl fumarate in multiple sclerosis treatment: an update to include China, using a modified Delphi method

R Gold, M Barnett, A Chan, H Feng… - Therapeutic …, 2023 - journals.sagepub.com
Dimethyl fumarate (DMF) is a widely used oral disease-modifying therapy for multiple
sclerosis (MS). Its efficacy and safety profiles are supported by over a decade of experience …

Co-occurrence of glioma and multiple sclerosis: prevailing theories and emerging therapies

E Kim, MC Fortoul, D Weimer, M Meggyesy… - Multiple Sclerosis and …, 2023 - Elsevier
Though the concurrence of primary brain tumors and multiple sclerosis (MS) is exceedingly
rare, instances have been noted in the literature as early as 1949. Given these observations …

The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from …

T Biernacki, D Sandi, J Füvesi, Z Fricska-Nagy… - Plos one, 2022 - journals.plos.org
Background Fingolimod was approved and reimbursed by the healthcare provider in
Hungary for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS) in …

Flow cytometry identifies changes in peripheral and intrathecal lymphocyte patterns in CNS autoimmune disorders and primary CNS malignancies

S Räuber, A Schulte-Mecklenbeck, A Willison… - Journal of …, 2024 - Springer
Background Immune dysregulation is a hallmark of autoimmune diseases of the central
nervous system (CNS), characterized by an excessive immune response, and primary CNS …

Exploring the role of sex hormones and gender diversity in multiple sclerosis

C Nesbitt, A Van Der Walt, H Butzkueven… - Nature Reviews …, 2024 - nature.com
Sex and sex hormones are thought to influence multiple sclerosis (MS) through effects on
inflammation, myelination and neurodegeneration, and exogenous hormones have been …

Multiple sclerosis and breast cancer risk: a meta-analysis of observational and Mendelian randomization studies

T Fang, Z Zhang, H Zhou, W Wu, L Zou - Frontiers in Neuroinformatics, 2023 - frontiersin.org
Background Several observational studies have explored the relationships between multiple
sclerosis (MS) and breast cancer; however, whether an association exists remains unknown …